Compare WVE & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | DEA |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2015 | 2014 |
| Metric | WVE | DEA |
|---|---|---|
| Price | $6.27 | $25.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 5 |
| Target Price | ★ $29.81 | $23.49 |
| AVG Volume (30 Days) | ★ 3.3M | 439.7K |
| Earning Date | 04-28-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.77% |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | $3,704,000.00 | ★ $336,099,000.00 |
| Revenue This Year | N/A | $5.41 |
| Revenue Next Year | $85.67 | $3.33 |
| P/E Ratio | ★ N/A | $1,256.00 |
| Revenue Growth | ★ 149.43 | 11.27 |
| 52 Week Low | $5.02 | $20.56 |
| 52 Week High | $21.73 | $25.38 |
| Indicator | WVE | DEA |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 67.89 |
| Support Level | $6.02 | $20.89 |
| Resistance Level | $6.31 | N/A |
| Average True Range (ATR) | 0.29 | 0.60 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 89.52 | 91.73 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.